- Home
- BRT vs NBP Comparison
BRT vs NBP Comparison
Compare BRT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | NBP |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 275.2M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRT | NBP |
|---|---|---|
| Price | $14.24 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.75 | $9.00 |
| AVG Volume (30 Days) | 22.9K | ★ 1.1M |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $1.91 |
| 52 Week High | $16.69 | $5.19 |
Technical Indicators
Market Signals| Indicator | BRT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 22.10 |
| Support Level | $13.18 | N/A |
| Resistance Level | $15.03 | $2.73 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 19.23 | 2.31 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.